

Changes in extracellular matrix in failing human non-ischemic and ischemic hearts with mechanical unloading

Citation for published version (APA):

Zhao, Y., Godier-Furnemont, A., Bax, N. A. M., Bouten, C. V. C., Brown, L., Fine, B., & Vunjak-Novakovic, G. (2022). Changes in extracellular matrix in failing human non-ischemic and ischemic hearts with mechanical unloading. *Journal of Molecular and Cellular Cardiology*, 166, 137-151.
<https://doi.org/10.1016/j.yjmcc.2022.02.003>

Document license:
TAVERNE

DOI:
[10.1016/j.yjmcc.2022.02.003](https://doi.org/10.1016/j.yjmcc.2022.02.003)

Document status and date:
Published: 01/05/2022

Document Version:
Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:


www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.



Changes in extracellular matrix in failing human non-ischemic and ischemic hearts with mechanical unloading

Yimu Zhao^{a,1}, Amandine Godier-Furnemont^{a,1}, Noortje A.M. Bax^{a,b,c}, Carlijn V.C. Bouten^{b,d}, Lewis M. Brown^e, Barry Fine^f, Gordana Vunjak-Novakovic^{a,f,*}

^a Department of Biomedical Engineering, Columbia University, New York 10032, USA

^b Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands

^c Center for Care & Cure Technology Eindhoven (C3Te), Eindhoven University, Eindhoven, the Netherlands

^d Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands

^e Quantitative Proteomics and Metabolomics Center, Department of Biological Sciences, Columbia University, New York 10027, USA

^f Department of Medicine, Columbia University, New York, NY 10032, USA

ARTICLE INFO

Keywords:

Extracellular matrix
Heart failure
Proteomics
Non-ischemic cardiomyopathy
LVAD support
Ischemic cardiomyopathy
Disease niches

ABSTRACT

Ischemic and non-ischemic cardiomyopathies have distinct etiologies and underlying disease mechanisms, which require in-depth investigation for improved therapeutic interventions. The goal of this study was to use clinically obtained myocardium from healthy and heart failure patients, and characterize the changes in extracellular matrix (ECM) in ischemic and non-ischemic failing hearts, with and without mechanical unloading. Using tissue engineering methodologies, we also investigated how diseased human ECM, in the absence of systemic factors, can influence cardiomyocyte function. Heart tissues from heart failure patients with ischemic and non-ischemic cardiomyopathy were compared to explore differential disease phenotypes and reverse remodeling potential of left ventricular assisted device (LVAD) support at transcriptomic, proteomic and structural levels. The collected data demonstrated that the differential ECM compositions recapitulated the disease microenvironment and induced cardiomyocytes to undergo disease-like functional alterations. In addition, our study also revealed molecular profiles of non-ischemic and ischemic heart failure patients and explored the underlying mechanisms of etiology-specific impact on clinical outcome of LVAD support and tendency towards reverse remodeling.

1. Introduction

Heart failure (HF) is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to maintain the metabolic requirements of the body. It is estimated that 6.2 million American adults were diagnosed with HF between 2013 and 2016 and, despite the research focus on early diagnosis and new therapeutic strategies, HF remains one of the most difficult diseases to treat [1]. HF is generally

categorized into ischemic and non-ischemic cardiomyopathy based on etiology. Ischemic cardiomyopathy (ICM) results from coronary artery disease (CAD) and myocardial infarction (MI) while non-ischemic cardiomyopathy (NICM) has a variety of etiologies including genetic, viral, toxic and idiopathic. Earlier epidemiological surveys and large-scale clinical trials suggested that the prognosis of ICM patients is worse than NICM patients [2,3], yet the guideline-directed therapy for systolic dysfunction remains the same regardless of etiology. [4] Thus, a better

Abbreviations: APC, Activated Protein C; AR, Aspect ratio; β 1AR, Adrenoreceptor Beta 1; bFGF, basic Fibroblast Growth Factor; BMP4, Bone Morphogenetic Protein 4; BTR, Bridge to Recovery; BTT, Bridge to Transplantation; CA2, Carbonic Anhydrase; CAD, Coronary Artery Disease; CM, Cardiomyocytes; DKK, Dickkopf protein; EB, Embryoid Body; ECM, Extracellular Matrix; EDTA, Ethylenediaminetetraacetic Acid; CMC, Cell/Matrix Construct; ESC-CM, Embryonic Stem Cell Derived Cardiomyocyte; FDR, False Discovery Rate; F-CMC, Failing Cell/Matrix Construct; GAGs, Glycosaminoglycans; GSEA, Gene Set Enrichment Analysis; HBSS, Hank's Balanced Salt Solution; HF, Heart Failure; ICM, Ischemic Cardiomyopathy; IHC, Immunohistochemistry; LBP, Lipopolysaccharide-binding Protein; LVAD, Left Ventricular Assist Device; MI, Myocardial Infarction; MMP9, Matrix Metalloproteinase 9; MTG, Monothioglycerol; NF-CMC, Non-failing Cell/Matrix Construct; NICM, Non-Ischemic Cardiomyopathy; PCA, Principle Component Analysis; -po, Post LVAD Surgery; -pre, Pre LVAD Surgery; RNAseq, RNA Sequencing; SAA1, Serum Amyloid A; SDS, Sodium Dodecyl Sulphate; VEGF, Vascular Endothelial Growth Factor.

* Corresponding author at: Department of Biomedical Engineering, Columbia University, New York 10032, USA.

E-mail address: gv2131@columbia.edu (G. Vunjak-Novakovic).

¹ Yimu Zhao and Amandine Godier-Furnemont are equally contributing co-first authors.

<https://doi.org/10.1016/j.yjmcc.2022.02.003>

Received 14 November 2021; Received in revised form 28 January 2022; Accepted 11 February 2022

Available online 24 February 2022

0022-2828/© 2022 Elsevier Ltd. All rights reserved.

understanding of disease mechanisms and developing etiology-specific therapeutic strategies are critical to improve patient care.

In native cardiac tissue, the extracellular matrix (ECM) is a critical component that interacts with cells and modulates tissue functions in both healthy and diseased states. ECM is a dynamic network of secreted proteins that provide structural and functional support, maintain mechanical integrity, storage and release of bioactive molecules, and serve as anchoring sites for the cells [5–8]. The heart ECM needs high compliance and stable mechanical support for the dynamic volumetric changes during contraction, which rely on the key ECM components, such as collagen, elastin and glycosaminoglycans (GAGs) [8–10]. Pressure overload induces alterations in the homeostasis of the ECM, exacerbating deterioration of cell function. ECM remodeling can dynamically adapt to stressors such as mechanical load [5] and alter its composition [11]. For example, myocardial damage resulting from external stressors leads to cardiac fibrosis, in which myofibroblasts are activated from mechanical loading [12] and deposit excessive amounts of collagen as a part of wound healing responses [13]. The altered ECMs appear different between non-ischemic cardiomyopathy (NICM), which typically has interstitial collagen deposition, and ischemic cardiomyopathy (ICM), which is more likely to have replacement fibrosis at the site of MI [14].

Decellularized tissues provide a unique opportunity to serve as cell-instructive scaffolds for engineering many tissue types, including the heart [15–18]. The first reports of decellularized hearts came in 2007 [16], followed by the use of cardiac-derived ECM in form of an entire organ, sheets and hydrogels, that were derived from rat, porcine and human hearts [19–22]. The cardiac-specific ECM was shown to be non-immunogenic and superior to collagen alone in preserving the left ventricular function [23]. Although decellularized cardiac ECM has been used to investigate its role in guiding stem cell fate [24], little is known about the regulatory roles of diseased ECM on cardiomyocytes. Thus, our study was motivated by the need to address this gap, using tissue engineering methodologies, with a focus on changes resulting from mechanical unloading. Recently, ECM-derived hydrogel was reported to preserve the biological content of ECM macromolecules, including collagen, fibronectin and laminin, in various tissue engineering applications [25]. However, the unique structure and mechanical characteristics of the diseased heart ECM are difficult to recapitulate using ECM-derived hydrogel. The use of decellularized heart sections, as in our previous studies of heart treatment by an engineered cardiac patch [26] allowed more comprehensive insights into cell-ECM interactions.

Left ventricular assist device (LVAD) is primarily used for end-stage heart failure patient to maintain their heart function while waiting for the transplantation, i.e. bridge to transplantation (BTT). In some cases, clinicians have reported myocardial recovery, in which patients have a sufficiently recovered systolic function to allow for LVAD explant instead [27–29]. During this process, LVAD support unloads the left ventricle, and this partially relaxed state of the left ventricle might result in tissue remodeling [30]. A study in 2016 reported that NICM is one of the six predictors of systolic function recovery after LVAD [29,31]. However, the underlying mechanisms are still unclear.

The specific goal of this study was to use decellularized heart ECM from healthy and heart failure patients to explore the differences between healthy and diseased human ECM. We also used tissue engineering methodologies to investigate how diseased human ECM, in the absence of systemic environment and other signaling components (inflammation, oxygen tension), can influence the cardiomyocyte function. To this end, we studied biopsied heart tissues from heart failure patients with ischemic and non-ischemic cardiomyopathy, that underwent LVAD surgery. Whenever possible, we obtained matching tissue samples from the same patient, before and after LVAD. ECM was analyzed for the composition and morphology and used for the cultivation of human cardiomyocytes derived from stem cells. Data were analyzed and interpreted to assess differential disease phenotypes and

investigate whether LVAD leads to a molecular recovery at the transcriptomic, proteomic and structural levels.

2. Results

2.1. Study design and patient information

We obtained left ventricular muscle samples from 20 patients with end-stage heart failure, of which 9 patients provided paired samples from LVAD surgery (NICMpre and ICMpre) and subsequent heart transplantation (NICMpo and ICMpo). Tissue samples were processed for analysis of gene expression and protein content. Table 1 summarizes the patient information and the inclusion of samples in RNAseq, proteomics analysis, and histological evaluation.

All patients underwent LVAD surgery before transplantation and the average waiting period was 393 days, ranging from 102 to 1414 days. Long-term patient tracking in this study was critical as a direct comparison of samples from before and after the LVAD procedure is particularly informative due to the high donor to donor variability. We also obtained non-failing (healthy) heart samples from healthy donors that failed to meet the transplantation screening criteria.

The experimental strategy is summarized in Fig. 1. First, the molecular compositions of the non-failing and failing ECM were investigated by proteomic analysis. Decellularized myocardium was used as a scaffold to probe how differential molecular compositions influence the functional performance of human stem cell-derived cardiomyocytes. Then, we investigated the differences between ICM and NICM ECM at the molecular level using proteomic analysis, RNAseq, and histology. Using similar approaches, the effect of mechanical unloading on disease progression was explored for ICM and NICM ECM.

2.2. Decellularized human heart proteomics reveal differences between failing and non-failing heart

Human myocardial samples from the left ventricular apex of 3 non-failing hearts and 4 ICM hearts obtained at the time of heart transplant were used for the proteomic analysis of ECM (Fig. 2A). The patient samples were decellularized and sectioned, as detailed in Methods (Fig. 2B). After ECM digestion and protein purification, we performed proteomics on these samples in duplicate. Among all the detected proteins, 362 proteins were identified by more than one peptide and were used for further analysis (Supplemental Table 1). Principal component analysis (PCA) of the entire proteomics data set showed a clear separation between ECM samples derived from heart failure versus healthy patients (Fig. 2C). Differentially expressed proteins were analyzed and plotted using false discovery rate (FDR) corrected *p*-values and fold changes between failing and non-failing heart samples (Fig. 2D). The most differentially expressed ECM proteins are shown in the heatmap (Fig. 2E). Nidogen-1, thrombospondin 1 and 4, fibrillin-1, Decorin, and Emilin-1 were more abundant in non-failing heart samples, whereas multiple types of collagen proteins, versican core protein, dermatopontin and prolargin were more abundant in the failing heart samples. We confirmed the expression changes of the four most abundant ECM proteins including vitronectin, nidogen, collagen (Picrosirius red) and laminin by histology staining (Fig. 2F).

2.3. ECM from failing hearts creates a diseased microenvironment impairing CM function and morphology

Because of the differential compositions of ECM proteins in the failing and non-failing heart, we explored whether ECM composition in the failing heart can act as a disease microenvironment and induce disease-like functional alterations in healthy cardiomyocytes. To this end, decellularized ECM from the failing hearts (ischemic) and healthy controls (non-failing, (NF)) were sectioned and used as a scaffold for stem cell-derived human cardiomyocytes (ESC-CM) to study the ECM-

Table 1
Patient information.

Patient	Condition	Gender	Age	Duration LVAD (Days)	RNA seq	Proteomics (Whole Tissue)	Proteomics (ECM)	Actinin	Vimentin	Elastin	Vinculin	Ncadherin	Fibronectin	Cx43	Picro sirius	ASMA
6A	NICM	M	36		Yes	-		Yes	Yes	Yes	Yes	Yes	Yes		Yes	
6B	NICM			616				Yes	Yes	Yes	Yes	Yes	Yes			
7A	NICM	M	32		-	Yes		Yes	Yes	Yes			Yes		Yes	
7B	NICM			257		Yes		Yes	Yes	Yes			Yes		Yes	
8A	NICM	M	58		-	Yes									Yes	
9A	ICM	M	64		-	Yes				Yes			Yes		Yes	
13B	ICM	M	53	262	-	Yes	Yes						Yes		Yes	
22B	ICM	M	61	322		Yes	Yes									
23A	ICM	M	60			Yes										
24B	ICM	M	71	378	-	Yes	Yes								Yes	
27A	NICM	F	22		-	Yes		Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
27B	NICM			221	-	Yes		Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
28B	NICM	M	63	277		Yes	Yes									
29A	NICM	M	47	418	-	-		Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
29B	NICM				-	-		Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
31A	ICM	M	65		-	Yes		Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
31B	ICM			439	-			Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
33B	NICM	M	36	1414	-	Yes		Yes	Yes	Yes	Yes	Yes	Yes		Yes	
34A	NICM	F	59	406	-	Yes		Yes	Yes	Yes	Yes	Yes	Yes		Yes	
41A	ICM	M	70		Yes			Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
41B	ICM			191	Yes			Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
50B	NICM	M	51	102	-	Yes		Yes	Yes	Yes	Yes	Yes	Yes		Yes	
53A	ICM	F	68		-	-		Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
53B	ICM			422	-	-		Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes
60A	NICM	M	49		Yes											
60B	NICM			395	Yes	-		Yes	Yes	Yes	Yes	Yes		Yes	Yes	Yes
65A	ICM	M	64			Yes										
82A	ICM	M	63		Yes	-		Yes	Yes	Yes		Yes	Yes	Yes		Yes
82B	ICM			173	Yes	-		Yes	Yes	Yes		Yes	Yes	Yes		Yes
HH1	Healthy				Yes	Yes	Yes									
HH2	Healthy				Yes	Yes	Yes									
HH3	Healthy						Yes									

cardiomyocyte cross-talk (Fig. 3A). Previous research has documented the ability of ECM to direct ESC fate, through essential crosstalk between ESCs and ECM receptors/growth factor receptors and transduction of mechanical signals [32,33].

The appearance of the cell/matrix construct (CMC) was documented by bright-field images in Fig. 3B. After two weeks of culture, CMCs were tested with isoproterenol, a positive inotropic and chronotropic beta-adrenergic agonist (Fig. 3C). The cumulative strain, measured as the summed strain rates per contractile events of EBs, was evaluated at baselined isoproterenol concentrations of 30 nM, 100 nM, 300 nM and 1 μ M, where NF-CMC reached strain plateau between 0 and 30 nM, and failing (F)- CMC peaked at 300 nM. ECM proteins, such as elastin and fibronectin were evaluated by immunohistochemistry (IHC) to compare the CMCs from different groups (Fig. 3D, Supplemental Fig. 1). We found reduced elastin and increased fibronectin in CMCs seeded on failing ECMs. We also investigated the expressions of cardiomyocyte proteins with immunohistology and found increased α -actinin, and reduced troponin organization in F-CMCs when compared to non-failing CMC. Non-myocyte populations, stained with vimentin, were increased in F-CMCs as well. These protein expressions had consistent trend when compared to the NF and HF whole tissue proteomics.

To compare protein expressions in CMCs and corresponding patient samples, we performed whole tissue proteomics with human myocardium derived from two normal hearts and four ICM failing hearts at the time of heart transplant. Whole tissue proteomics revealed 571 proteins (Supplemental Table 2) with more than one peptide, and differentially expressed proteins are shown in the heatmaps (Fig. 3E). Interestingly, the expression changes of α -actinin, troponin, and vimentin from IHC on

F- and NF-CMCs (Fig. 3D) were consistent with the whole tissue proteomics performed on these patient samples (Fig. 3E). These results suggested that ECM from heart failure patients have the altered molecular composition that may contribute to the diseased microenvironment, mimicking local changes experienced by cardiomyocytes in vivo. In addition, these changes could cause disease-like functional alteration on healthy CMCs.

2.4. Whole tissue proteomics and RNA-seq demonstrated different patterns between NICM and ICM patients

In an effort to delineate the different molecular profiles between ICM and NICM failing hearts, we performed whole tissue proteomic analysis of whole tissue samples from 4 ICM patients and 4 NICM patients (Fig. 4A and Supplemental Table 2). PCA showed separation between ICM and NICM patients with 61% variance for the first principal component (Fig. 4B). Differentially expressed proteins were further analyzed and compared with non-failing samples. NICM samples had 32 differentially expressed proteins and ICM samples had 185 differentially expressed proteins, compared to non-failing samples (Fig. 4C). All differentially expressed proteins were plotted using false discovery rate (FDR) corrected *p*-values and fold changes between NICM and ICM samples (Fig. 4D).

Interestingly, the most enriched proteins in ICM, Serum Amyloid A 1 (SAA1) and Lipopolysaccharide-binding protein (LBP) are clinical biomarkers associated with coronary artery disease (CAD) [34–36]. Another highly enriched protein in ICM, activated protein C (APC), functions as a natural anticoagulant to downregulate thrombin




Fig. 1. Experimental design overview. Healthy and heart failure patient samples were decellularized, sectioned and seeded with human stem cell derived cardiomyocytes (CM). A disease-like phenotypic and functional modulation through the ECM from heart failure patient samples was demonstrated with previously healthy CMs. In addition, heart failure patient samples were profiled and compared at a molecular level to understand the etiological differences between NICM and ICM and the therapeutic potential of LVAD.

generation in the clotting cascade, exhibiting strong cytoprotective and anti-inflammatory activity. On the other hand, NICM enriched proteins, NDUFS7 and NDUFA6, are both proteins involved in the largest enzyme of the mitochondrial membrane respiratory chain (NADH: ubiquinone oxidoreductase complex I) [37,38]. The enrichment of these proteins in NICM groups may suggest a higher level of mitochondria-related cellular activity.

Gene ontology term pathway analysis of differential proteomic expression demonstrated upregulation of ECM organization, contractile function and immunological responses in ICM myocardium, whereas NICM myocardium displayed upregulation of oxidoreductase activity (Fig. 4E). In terms of differentially expressed proteins, ICM samples showed upregulation of cardiac sarcomere proteins, such as multiple myosin proteins, tropomyosin 3, cadherin 13 and actin proteins. There were also various types of collagens, collagen fragments (endostatin), β 2-glycoprotein 1, and a matrix degradation protein, matrix metalloproteinase 9 (MMP9), that were upregulated in ICM samples. The elevated vimentin, a classic non-myocyte marker, indicating the increased non-myocyte population in ICM that was consistent with elevated collagen secretion. NICM samples, on the other hand, had more expressions on mitochondria-related proteins, indicating the potential higher cellular activities, such as metabolism and oxidative phosphorylation (Fig. 4F). The Gene Set Enrichment Analysis (GSEA) of proteomics revealed similar findings, in which ICM samples had upregulation of inflammatory responses, pathways related to wound healing and phagocytosis and NICM samples had higher fatty acid oxidation and metabolic activities (Fig. 4G).

We further compared these data with the RNAseq dataset (Supplemental Fig. 2, Supplemental Table 3), performed on two ICM and two NICM patient samples. Although the separation between NICM and ICM samples was shown by PCA, unsupervised hierarchical clustering of samples did not correspond to the etiological differences. GSEA demonstrated enriched striated muscle contraction, cardiac contractile machinery and fibroblast development in ICM patient samples, which







were consistent with proteomics data.

We also performed histology staining and quantification of samples from NICM and ICM patients ($n = 4$ per group) to evaluate cardiac functional proteins by Troponin T and N-cadherin; extracellular collagen deposition by Picro Sirius Red and fibronectin (Supplemental Fig. 3). When directly comparing NICMpre and ICMpre (patient samples before LVAD), ICM patients tended to have a higher expression of troponin T, better aligned N-cadherin, more collagen deposition and similar fibronectin expression compared to NICM patients (Supplemental Fig. 3). These results were consistent with the proteomic and RNAseq analyses.

In summary, the analysis of whole tissue proteomics and RNAseq datasets and histology demonstrated upregulated inflammation responses, higher expressions of sarcomere proteins, elevated ECM protein secretion and increased non-myocyte populations in ICM samples. NICM samples showed enriched metabolic activity that related to mitochondrial function.

2.5. LVAD attenuated NICM disease progression

We obtained myocardial tissues from four NICM patients during LVAD surgery (NICMpre) and after heart transplantation (NICMpo), to investigate how LVAD influenced the progression of ECM through the analysis of whole tissue proteomics (Fig. 5 and Supplemental Table 2) and RNAseq based gene expressions (Supplemental Fig. 4, Supplemental Table 3). All proteins from the proteomic dataset were included for PCA and there was an incomplete separation between NICMpre and NICMpo samples (Fig. 5B). NICMpre and NICMpo were compared to healthy donors respectively to identify their differentially expressed proteins, where NICMpo samples had 32 differential expressed proteins and NICMpre samples had 55 differential expressed proteins, compared to non-failing samples. NICMpre and NICMpo shared 17 differential expressed proteins with non-failing samples (Fig. 5C). The reduction of differentially expressed proteins after LVAD suggested that NICMpo



(caption on next page)

Fig. 2. Proteomics reveals differences in ECM composition and protein expression between Non-Failing and Failing human hearts. A) overview; B) heart explant and the processed decellularized ECM; C) Principal component analysis of proteomics obtained from decellularized ECMs of non-failing and failing patient samples; D) Volcano plots indicating significantly altered proteins identified in the proteomic datasets from decellularized ECMs of non-failing and failing hearts. Negative log-transformed *P*-values (two-tailed Student's *t*-test associated with individual proteins plotted against the difference in means of log₂-transformed normalized values for individual proteins. E) Heatmap representing the expression of selected ECM proteins across non-failing and failing patient samples. F) Representative histology staining for ECM proteins from non-failing and failing patient samples, including vitronectin, nidogen, laminin and Picro Sirius Red for collagen. Patient samples involved were HH1, HH2 and HH3 (*n* = 3) for non-failing ECMs and 13B, 22B, 24B, and 28B, (*n* = 4) for failing ECMs (ICM after LVAD). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

resembled better with non-failing samples.

We further directly compared NICMpre and NICMpo samples for differentially expressed proteins, (Fig. 5D) all of which were included in the volcano plot using FDR corrected *p*-values and fold changes between NICMpre and NICMpo samples. Tropomyosin 1,2 and 3 were among the most upregulated proteins in NICMpo samples. Tropomyosin is the key regulatory component of the thin filament and plays a central role in the cardiac muscle's cooperative activation mechanism [39]. Similarly, small calcium (Ca²⁺)-binding protein (S100A1) that was upregulated in NICMpo, is a key regulator of cardiac performance, by controlling Ca²⁺-influx and restoration [40,41]. On the other hand, carbonic anhydrase 2 (CA2), showed the highest upregulation in NICMpre, is a marker for cardiac hypertrophy and ICM progression [42,43]. Moreover, GO term pathway analysis showed upregulation of CM function-related proteins and downregulation of ECM region activity in NICMpo (Fig. 5F). The trends of reduced collagen deposition in NICMpo histologically and the elevation of cardiac function-related pathways from GSEA were also in agreement with this finding (Supplemental Fig. 3, Fig. 5G).

The proteomics data were further confirmed by RNAseq analysis (Supplemental Fig. 3). We included NICMpre, NICMpo and non-failing samples in the comparison. Both the PCA plots and correlation based hierarchical clustering of experimental groups demonstrated better resemblance of NICMpost myocardium with non-failing samples. When comparing between NICMpre and NICMpo, GSEA also showed depleted immune responses and mitochondria activity, more enriched sarcomere proteins and action potential related gene sets in NICMpo.

Cell-cell interaction is the key regulator of mechanical and electrical coupling between cardiomyocytes that maintains cardiac function. The intercalated disc complex located at the transverse junction between cardiomyocytes is responsible for such communication and can be significantly reduced in heart failure patients [44]. Since we found significant enrichment in cell adhesion pathways in NICMpo, adherens junction N-cadherin and gap junction connexin 43 (Cx43) were assessed. Consistently with pathway analysis, tissue histological staining of N-cadherin showed significantly increased expression after LVAD (*n* = 4, paired *t*-test, *p* = 0.0151, Supplemental Fig. 3), while RNA level of N-cadherin showed a trend of increase after LVAD. Cx43 staining also trended higher in NICMpo group (data not shown). GSEA from RNAseq confirmed the enrichment in cell-cell signaling and cardiac conduction (Supplemental Fig. 4 and Supplemental Table 3).

These results demonstrated that after LVAD, NICMpo samples resembled more closely the non-failing samples in terms of protein and RNA expressions. Compared to NICMpre, NICMpo exhibited enrichment of S100A1, tropomyosin, α -actinin and other cardiac functional proteins, as well as increased adherens junction protein N-cadherin. There were enriched GO term pathways in cardiac contraction and contractile machinery and reduced ECM activity in NICMpo. Also, GSEA showed enrichment of cardiac contractile proteins and reduced inflammation. All of the above data were consistently supported that the LVAD procedure attenuated the molecular markers of NICM.

2.6. Comparison of ICM patient samples before and after LVAD

Myocardial tissues from four ICM patients during LVAD surgery (ICMpre) and after heart transplantation (ICMpo) were compared to investigate how LVAD influences the progression of ICM through the analysis of whole tissue proteomics (Fig. 6 and Supplemental Table 2)

and RNAseq based gene expressions (Supplemental Fig. 5, Supplemental Table 3).

PCA from whole tissue proteomics did not show a good separation between ICMpre and ICMpo samples (Fig. 6B). When ICMpre and ICMpo were compared to non-failing samples to identify differentially expressed proteins, ICMpre and ICMpo samples had 185 and 177 differentially expressed proteins, respectively, compared to non-failing samples (Fig. 6C). When ICMpre and ICMpo were compared for their differentially expressed proteins, volcano plot revealed the most upregulated proteins in ICMpo groups. In particular, ASPN has been demonstrated to be a potential biomarker for heart failure [45], and periostin (POSTN) that has been associated with myocardial fibrosis in human failing hearts were highly upregulated (Fig. 6C). A list of most differentially expressed proteins is included in the heatmap. ICMpo samples had enriched collagen proteins and immunoglobins, whereas ICMpre had higher levels of N-cadherin (cadherin 2). Both ICMpre and ICMpo samples had different types of enriched sarcomere proteins and mitochondrial membrane proteins (Fig. 6D). GO terms pathway analysis showed upregulation of ECM organization and downregulation of mitochondria, respiration, fatty acid metabolism, CM contraction-related pathways in ICMpo samples (Fig. 6E). GSEA of differential protein expression indicated downregulated immune response and stress-related pathways, as well as cell proliferation in ICMpo (Fig. 6F).

For RNAseq analysis, both PCA plots and hierarchical clustering of samples were created among ICMpre, ICMpo and non-failing samples, and the three groups did not clearly separate. GSEA of RNAseq also showed enriched genes in ECM organization and collagen production, which is consistent with GO terms pathway analysis (Supplemental Fig. 5). Based on these results, LVAD treatment did not result in significant changes in either protein or RNA expression in ICM tissues.

3. Discussion

Although biological specimens have been collected for use in a variety of molecular epidemiology, clinical trials and basic research studies for years, human cardiac specimens are particularly difficult to obtain due to their non-regenerative and vital nature. Nevertheless, as heart failure involves the pathological interactions among the immune system, vascular network, cardiac muscles and electrical conduction systems, the complexity of the disease requires clinical samples to investigate the entire context. On the other hand, researchers can generate in vitro cardiac tissue models such as cardiac organoids and heart-on-a-chip with the recent technological advances in in vitro culture systems and induced pluripotent stem cells [46–48]. These tissue models are very versatile tools that enable the dissection of the individual contribution of cells and matrix to the diseases in a precisely controlled and biomimicry microenvironment. Therefore, in this study, we uniquely combined both approaches to carry out an in-depth investigation of the disease mechanisms. We first obtained human healthy and heart failure samples as well as the longitudinal tissue samples across a period up to 4 years for paired before and after LVAD implantation. We identified the alteration of molecular composition from decellularized ECM as a disease niche in heart failure samples and validated it with our in vitro CMCs.

We demonstrated molecular differences between ECMs from non-failing and failing hearts, consistent with the notion that ECM is the essential part of the myocardium that interacts with cells. For example,





Fig. 3. ECM from non-failing and failing hearts has differential effects on morphology and function of cultured cardiomyocytes. A) illustration of using decellularized ECM as a scaffold to create engineered cardiac tissue. B) Representative bright-field image of engineered heart tissue using ECM-derived scaffold. C) Cumulative strain was evaluated on CMC with different doses of isoproterenol, Mann Whitney test, $p = 0.13$. D) Confocal images of CMC grown using ECM from non-failing and failing heart patients stained with α -actinin (green), fibronectin (red), and Troponin (red), scale bar = 100 mm E) Heatmap of differentially expressed proteins between non-failing and failing heart patient samples, including proteins that constitute cardiac-specific contractile filaments and cytoskeletal components, as well as the ones responsible of mitochondria energy production. Patient samples involved were HH1 and HH2 ($n = 2$) for non-failing samples and 13B, 22B, 24B, and 28B, ($n = 4$) for failing samples (ICM after LVAD). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

nidogen is a basement membrane glycoprotein and the knockout studies in mice have shown to be important for cardiac tissue integrity [49]. Studies with human myocardium as well as models of pressure overload in rodents demonstrated that Nidogen is downregulated in heart failure [50], which is consistent with our findings. Similarly, thrombospondins are glycoproteins responsible for cell-cell adhesion and cell-matrix interaction, which was reported to decrease in failing hearts [51]. On the other hand, as the top upregulated ECM protein in failing samples,

dermatopontin was shown to interact with other ECM components, especially decorin, to regulate ECM formation. A rodent model demonstrated an elevated mRNA level of dermatopontin after MI that was consistent with our finding [52] Similarly, prolargin protein level was also elevated in heart failure patients [53].

When culturing human cardiomyocytes on diseased ECMs, cardiac function and secreted proteins were significantly affected and became aligned with the in vivo diseased state. We found reduced elastin and



(caption on next page)

Fig. 4. Differences in proteomics and RNASeq between tissues from ischemic and non-ischemic heart failure patients A) Heart failure can have different etiologies, such as ICM and NICM. B) Principal component analysis of whole tissue proteomics of non-failing and failing heart patient samples showed clear segregation of two types of heart failure conditions. C) Venn diagram reveals the overlap of significantly enriched annotations among datasets (FDR < 0.1, minimum fold change = 1.3). D) Volcano plots indicating significantly altered proteins identified in the proteomic datasets from whole tissue proteomics. Negative log-transformed *P*-values (two-tailed Student's *t*-test) associated with individual proteins plotted against the difference in means of log2-transformed normalized values for individual proteins. E) Differentially expressed genes in GO terms and KEGG were identified via the STRING API [56] for enrichment analysis, where enrichment in ICMpre (ICM before LVAD surgery) is demonstrated in red bars and NICMpre (NICM before LVAD) is blue bars. F) Heatmap representing the differential expressed proteins across ICM and NICM patient samples. G) GSEA pathway analysis of proteomics (biological process) demonstrates the enriched pathways in ICMpre (green) and NICMpre (red) using pathway tree. Patient samples were 8A, 34A, 7A, and 27A (*n* = 4) for NICM whole heart tissues and 9A, 23A, 31A, and 65A, (*n* = 4) from ICM whole heart tissues, both before LVAD. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

increased fibronectin in CMCs seeded on failing ECMs, which were consistent with the literature. While the exact mechanisms are still under investigation, the study showed that the increase in fibronectin content after MI [54] was associated with the increased abundance of cardiac myofibroblasts. Also, fibronectin polymerization was necessary for collagen matrix deposition, and fibrosis was attenuated while inhibiting fibronectin production. [55] The reduction of elastin expression in heart failure patient samples may stem from the reduced protein expression of Emilin-1, the elastin receptor, which eventually results in the reduction of tissue compliance due to the gradual replacement of elastin with collagen content in ECM after injury [56]. Reduced cardiac functional proteins and increased non-myocyte population suggested a shift from normal to fibrosis state. The lower sensitivity of isoproterenol was also in agreement with the pathological phenotype, as a result of their cell-matrix interactions. These differential cellular performances suggest an essential regulatory role of ECM from both healthy and diseased tissues.

Compared to NICM, ICM patient samples preserved better their cardiac functional proteins, elevated ECM depositions, and had a higher level of inflammatory response than NICM patients. In ICM patients, ventricular dysfunction is a consequence of myocardial ischemia and infarction related to coronary arteriosclerosis. Because damage and remodeling are more restricted to the infarct sites, ICM are often accompanied by a higher level of immune responses, which was identified with our proteomic analysis [57]. NICM often results from pressure overload, in which the disease alteration is presented for the entire pressure bearing chamber. This process relates less to immune responses and more directly to the myofibroblast activation via mechanosensing and TGF- β signaling [58].

NICM is broadly defined as cardiomyopathy without CAD, with varying etiologies. Subtypes such as hypertrophic and dilated cardiomyopathy often result from high blood pressure and chronic cardiac overload. LVAD procedure can remove the pathological trigger through mechanical unloading and facilitate cardiac recovery. This attenuation of disease phenotypes potentially through N-cadherin-dependent mechanosensing cascade [59]. In this study, the proteomic and RNAseq analysis consistently identified the gene sets and pathways related to upregulated cardiac contractile functions, signal transduction, and downregulated inflammatory responses in NICMpo. The histology staining of heart tissues from NICMpre and NICMpo confirmed the improved Troponin T expressions, as well as the upregulated N-cadherin after the LVAD.

Interestingly, ICM patients did not show the same responses. Although the inflammatory pathways are downregulated as well, the pathways of cellular activities including metabolism, cellular respiration, muscle contraction are downregulated simultaneously. The most noticeable upregulation in ICMpo are the pathways related to the increased non-myocyte populations and ECM matrix organization, which indicates the fibroblasts were activated and scar formation was still progressive. Both Troponin T and N-cadherin demonstrated a trend of down-regulation, suggesting reduced cardiac function. It is possible that the mechanical unloading in ICM patients is interfering with the necessary mechanical stimulation required for the heart to maintain its homeostatic function [60,61].

In a study of 15,138 patient outcomes in the INTERMACS cohort,

LVAD was evaluated as a potential therapeutic strategy – bridge to recovery (BTR) instead of conventional BTT and the author constructed a recovery predictive model. NICM is one of the six independent predictors for cardiac recovery of LVAD [29]. Other studies also confirmed that positive clinical outcomes are strongly associated with NICM patients [27–29,31].

Our findings are aligned with these studies of cardiac recovery after long-term LVAD, providing a more in-depth investigation at a molecular level to explain the etiology-specific preference of BTR therapy with LVAD. Despite the patients under current investigation being categorized in bridge to transplant group, which is not typically suitable for BTR therapy, the NICM patients still demonstrated a moderate level of functional recovery evident from the elevated cardiac function proteins. ICM patients, on the other hand, showed depletion of cardiac functional proteins, reduced levels of mitochondria-related activities, such as oxidative phosphorylation and various metabolic processes, and down-regulation of inflammatory gene sets. The reduced cardiac functions and cellular activities strongly indicated ICM patients may not benefit from the BTR therapy.


The primary limitation of this study is the small sample sizes, which were dictated by the availability of clinical samples. We only had four biological replicates for proteomics and two for RNAseq from heart failure patients to compare with 2–3 non-failing patient samples. Moreover, although both histology quantification and RNAseq data were obtained using paired patient samples before and after LVAD, we were only able to include two pairs from the same patients and two mismatched pairs for proteomic analysis. Therefore, donor variability would be a concern as well.

Intragroup variability was also observed in the non-failing group and ICMpo group (1 vs 2–4). Low sample sizes, sample mismatch, and intragroup variability can significantly reduce the power of analysis. As the intragroup variability results from donor variability, the molecular composition of non-failing and failing tissues can vary based on age, gender, environmental factors, and diseases related or unrelated to the heart [62]. Surgical harvest of heart tissue can also contribute to the intragroup variability due to the slight differences in the region of operation. Larger sample sizes would reduce the noise and to distill the critical mechanistic information, but are difficult to obtain, especially the matched samples before and after the intervention.

Despite these limitations, our histology and RNAseq experiment were performed on matched pairs which minimized the effects of donor variability. The consistency among proteome, transcriptome, and protein expressions in histological staining allowed us to reach conclusions, in spite of low sample sizes, donor variability, and sensitivity in techniques.

The LVAD effect on histological quantifications, such as cardiac fibrosis and N-cadherin, had a consistent trend in every patient before and after LVAD. Although high donor to donor variability leads to no significant differences, the strength of the analysis lies in the consecutive measurements in the same patients before and after LVAD implantation, in this way eliminating the variable results due to variations in patient population. This study is setting the first steps in understanding the contribution of LVAD support on cardiac recovery and therefore providing valuable information to the research field.

In conclusion, this proof-of-concept study demonstrated the impact



(caption on next page)

Fig. 5. LVAD procedure attenuates NICM disease phenotype, as demonstrated by proteomics and RNASeq data analysis. A) Patient samples were collected during LVAD surgery (NICMpre, heart tissues before LVAD support) and after transplantation (NICMpo, heart tissues after a significant period of LVAD support). B) Principal component analysis of whole tissue proteomics of NICMpre and NICMpo, suggesting potential segregation between NICMpre and NICMpo. C) Venn diagram reveals the overlap of significantly enriched annotations among datasets (FDR < 0.1, minimum fold change = 1.3). NICMpo-H had 60% fewer differential expressed proteins compared to NICMpre-H. D) Volcano plots indicating significantly altered proteins identified by whole tissue proteomic analysis of NICMpre and NICMpo tissues. Negative log-transformed P-values (two-tailed Student's t-test) associated with individual proteins plotted against the difference in means of log₂-transformed normalized values for individual proteins. E) Heatmap representing the differential expressed proteins in tissues from NICMpre and NICMpo patients. F) Differentially expressed genes in GO terms were identified via the STRING API [56] for enrichment analysis; enrichment in NICMpre and NICMpo are demonstrated by blue bars and red bars, respectively. G) GSEA pathway analysis of proteomics using a pathway tree demonstrates enriched pathways in NICMpre (green) and NICMpo (red) tissues. Patient samples were 8A, 34A, 7A, and 27A (n = 4) for NICM before LVAD and 7B, 27B, 33B, and 50B, (n = 4) from ICM after LVAD. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

on the ECM niche and its effect on functional alteration of cardiomyocytes towards in vivo diseased state. This study also revealed molecular profiles of NICM and ICM heart failure patients and explored the underlying mechanisms of etiology-specific impact on clinical outcome of LVAD support and tendency towards reverse remodeling.

4. Methods

4.1. Procurement of patient heart tissues

Myocardial tissue samples were obtained from the apical core biopsy during LVAD implantation and subsequently at the time of cardiac transplantation after LVAD-support. Detailed information is presented in Table 1. Patient consent was obtained and tissue was collected according to Columbia University's International Review Board protocol for de-identified tissue/data.

4.2. Preparation of decellularized scaffolds

Sections of the human myocardium were decellularized using a modified version of a protocol we previously described [63]. At the time of sample collection, the human myocardium was flash frozen and stored at -80 °C, until the time of use. Briefly, tissue samples were sectioned into 240 µm slices on a cryotome, washed in deionized water for 20 min, followed by 2 h of lysis in 10 mM Tris buffer and 0.1% wt/vol EDTA, followed by 6 h of solubilization in 0.5% SDS with orbital mixing. Sections were washed in PBS, incubated in PBS containing 50 U/ mL of DNase (Sigma-Aldrich) and 1 U/mL, and washed in HBSS with orbital mixing to remove the detergent and cell debris. These sections were either used to characterize the tissue ECM or as scaffolds for the cultivation of human cardiomyocytes.

4.3. Cell preparation

Cardiomyocytes were generated from human embryonic stem cell line HES2 according to a previously published protocol [64]. Briefly, embryoid bodies were formed by plating small aggregates of human ESCs in 2 mL basic media (StemPro34, Invitrogen, containing 2 mM glutamine, 4 × 10⁻⁴ M monothioglycerol (MTG), 50 µg/mL-1 ascorbic acid, Sigma, and 0.5 ng/mL-1 BMP4). At days 1–4, BMP4 (10 ng/mL), bFGF (5 ng/mL) and activin A (3 ng/mL) were added for primitive-streak formation; at days 4–8, VEGF (10 ng/mL) and DKK1 (150 ng/mL), were added for mesoderm induction; after day 8, VEGF (10 ng/mL), DKK1 (150 ng/mL), and bFGF (5 ng/mL) were added for cardiac specification. Cultures were maintained in a 5% CO₂/5% O₂/90% N₂ environment for the first 10–12 days and transferred to a 5% CO₂/air environment for culture maintenance.

4.4. Cell/matrix constructs

Decellularized human scaffolds were cut into 2 mm × 5 mm scaffolds and placed into flat-bottom, ultra-low attachment 96 well plates (Costar). On day 23, embryoid bodies from cardiac differentiation culture were dissociated using Blendzyme TM (Roche) in HBSS at 37 °C for

40 min. The dissociated cardiomyocytes were mechanically agitated, pelleted, and resuspended in basic media [64]. Cardiomyocytes were seeded onto decellularized scaffolds using 10⁵ cells per scaffold in 0.2 mL basic medium. Cells were cultured on scaffolds for 2 weeks, with medium change every other day.

4.5. Functional analysis


On day 14, the contractile behavior of the construct was assessed by video analysis during various interventions. Tissue constructs were placed into Tyrode's solution containing 140 mM NaCl, 5.4 mM KCl, 1 mM MgCl₂, 10 mM glucose, 0.4 mM CaCl₂ and 10 mM HEPES (pH 7.4 with NaOH at 25 °C) (adapted from [66]). Under video analysis (60 fps, 10× magnification), baseline beating was recorded followed by stepwise isoproterenol stimulation from 0.01 µM to 1 µM, at 4-min intervals. Videos were analyzed for cumulative strains of construct under isoproterenol stimulation, according to methods developed by Kamgoue et al. [67,68]. As EBs beat, grey intensity patterns were measured by the built-in cross-correlation function comparing interrogation areas between two adjacent frames, and generated velocity vectors between the areas of similar intensity. Strain rate was determined using built-in PIVlab functions of MATLAB, and compared with point-to-point contraction/relaxation data. An integral of the strain rate over the beating area was determined for each frame and averaged over the entire area of interest, resulting in a strain rate that could be traced over time. Positive strain rates for the contractile events were summed up to determine the cumulative strain, and divided by the number of contractions to determine the strain per beat.

4.6. Immunohistochemistry

For histology, pieces of native human heart tissue were fixed in 4% Formalin for 24 h at 4 °C, embedded in paraffin and sectioned at 5 µm. Tissue sections were mounted on polylysine-coated microscopy slides. To assess the presence of collagen, serial sections were stained with picrosirius red according to standard histological procedures and analyzed using a light microscope (Zeiss or Nikon).

For immunofluorescence, sections were stained according to standard immunohistochemistry protocols (Supplemental Table 4). Briefly, slides were deparaffinized in CitriSolv (Decon Labs, Inc), rehydrated and subjected to heat-induced epitope retrieval with Tris-EDTA (10 mmol/L Tris +1 mmol/EDTA) or citrate (10 mM citric acid, 0.02% Tween PH 6.0) buffer, respectively. Incubation with antibodies (Supplemental Figure 1) was followed by visualization by incubation of different Alexa-conjugated fluorescent secondary antibodies (Invitrogen, see Supplemental Figure 1). Sections were mounted with Fluoromount-G mounting media with DAPI (glycoMATRIX).

Semi-quantitative analyses of the images were performed using ImageJ software and in-house designed Matlab scripts and a minimum of 8 images of random field per cardiac tissue were analyzed. The percentage fibrosis was determined with semi-quantification of picrosirius red staining and the percentage fibrosis was expressed as the average ratio of total collagen area divided by the total myocardial area of the whole image. The same approach was used to determine the percentage



(caption on next page)

Fig. 6. LVAD procedures do not influence disease phenotypes in ICM patients. A) Patient samples were collected during LVAD surgery (ICMpre, heart tissues before LVAD support) and after transplantation (ICMpo, heart tissues after a significant period of LVAD support). B) Principal component analysis of whole tissue proteomics of ICMpre and ICMpo, suggested no segregation between ICMpre and ICMpo. C) Volcano plots indicating significantly altered proteins identified from whole tissue proteomics between ICMpre and ICMpo. Negative log-transformed P-values (two-tailed Student's t-test) associated with individual proteins plotted against the difference in means of log2-transformed normalized values for individual proteins. Venn diagram reveals the overlap of significantly enriched (FDR < 0.1, minimum fold change = 1.3) annotations among datasets, where ICMpo-H has slightly fewer differential expressed proteins than ICMpre-H. D) Differentially expressed genes in GO terms were identified via the STRING API [56] for enrichment analysis. E) Heatmap representing the differentially expressed proteins in ICMpre and ICMpo patient samples. F) GSEA pathway analysis of proteomics demonstrates the enriched pathways in ICMpo (green) and ICMpre (red) using a pathway tree. Patient samples were 9A, 23A, 31A, and 65A (n = 4) for ICM whole heart tissues harvested before LVAD and 13B, 22B, 24B, and 28B, (n = 4) from ICM whole heart tissues harvested after LVAD. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

area staining positive for elastin. The numbers of cells expressing Fibronectin around the nucleus were counted using ImageJ. Comparison between pre- and post-LVAD groups for all patients were performed within the same staining procedure. To determine the percentage of cardiac fibroblasts in the myocardium, α -actinin and vimentin-positive cells were quantified by an in-house designed Matlab script counting number of “green” and “red” stained cells.

To determine the aspect ratio (AR) of the N-cadherin and Connexin 43 (Cx43) expression at the intercalated disc, an in-house Matlab script was designed. Images were semi-automated binarized to detect and measure the ellipses of intercalated discs using the Cx43 and N-cadherin markers. As a result of cardiac injury, redistribution of Cx43 to the intercalated discs on the lateral sides of the cardiomyocytes, results in a reduction of the aspect ratio of the ellipse, closer to a circular aspect ratio of 1.

All quantified data are presented as mean \pm SD. Statistical analysis of the results was accomplished by the non-parametric Mann-Whitney test to compare the grouped samples. Statistical analysis was performed for multiple comparisons a Kruskal-Wallis assuming non-equal variances, with Dunn's post-hoc test. Statistical significance was considered when $P < 0.05$. Graphics and statistical analysis were performed using the Graphpad Prism 5.04 software package (Graphpad Software). More information on the in-house designed Matlab script can be provided on request (m.c.v.turnhout@tue.nl).

4.7. Protein extraction, purification and proteomics analysis

Mass spectrometry and data analysis methods have been described previously [69,70]. In brief, for decellularized tissue, three non-failing and four failing human hearts were studied. Flash-frozen myocardium-derived decellularized scaffolds were pulverized in liquid nitrogen using a mortar and pestle. The pulverized tissue was then homogenized in lysis buffer (pH 7.5) containing 50 mmol/L Tris, 150 mmol/L NaCl, 0.3% sodium dodecyl sulfate and 1% protease inhibitors. Protein extraction was performed using TRIS-buffered saline with 0.3% sodium dodecyl sulfate followed by chloroform-methanol precipitation. Precipitated protein was dissolved in 0.1% RapiGest (Waters Corp) in 50 mM ammonium bicarbonate. Cysteines were reduced with dithiothreitol at 60 °C for 30 min, followed by bath sonication, and then boiled for 5 min to ensure proteins were dissolved. Cysteines were alkylated with iodoacetamide for 30 min at room temperature, with no centrifugations before digestion with porcine trypsin to minimize any loss of poorly soluble proteins. After RapiGest cleavage according to the manufacturer's directions, samples were centrifuged at 16,000 x G for 30 min to remove RapiGest cleavage products. A digest with 50 fmol of yeast alcohol dehydrogenase was added as an internal detection control. Peptides were separated on NanoAcquity liquid chromatography coupled to a Synapt G2 HDMS quadrupole time-of-flight mass spectrometer (Waters Corp). Two 120 min liquid chromatography runs were performed with acetonitrile: water gradient for each biological replicate in resolution/ion mobility mode (traveling wave ion mobility spectrometry (TWIMS) (total of 14 LC/MS/MS chromatograms). Every 30s a lockmass spectrum of doubly charged Glu-1-Fibrinopeptide B at (m/z 785.8426) was recorded from the reference sprayer. Label-free quantitation was performed with Progenesis QI for Proteomics (Waters Corp.)

with database search against a UniProt database of human sequences (release 2013.11) including porcine trypsin, yeast alcohol dehydrogenase and sheep keratin.

Raw mass spectrometry data are made available at the MassIVE repository (<https://massive.ucsd.edu/>) as dataset MSV000088676 with raw files located at <ftp://massive.ucsd.edu/MSV000088676/>.

Ischemic and non-ischemic tissues from cardiomyopathy patients were analyzed: NICMpre, NICMpo, ICMpre, ICMpo, Healthy (four biological replicates for all diseased samples, two replicates for healthy samples). Two LC/MS chromatograms were recorded for each biological replicate (a total of 36 LC/MS/MS chromatograms for 18 samples). Methods were the same as described above for decellularized tissues. Low amounts of protein in small CMCs grown in vitro necessitated mass spectrometry data collection in instrument sensitivity mode instead of resolution/ion mobility mode (TWIMS). Sensitivity data were analyzed with ProteinLynx Global Server V.2.5, RC9, (Waters Corp) followed by label-free intensity-based quantitation with Rosetta Elucidator software Ver. 3.3.0.1.SP3_CRE52.21 (Ceiba Solutions, Inc.) that employs the peptide teller algorithm as described previously [71].

Differential protein expressions and GSEA analysis of proteomic data for whole tissues were done using the iDEP web tool (version 0.92, <http://bioinformatics.sdstate.edu/idep/#>) [72]. Briefly, FDR and fold changes (FC) for proteins were analyzed with DESeq2. All differentially expressed proteins (FDR cutoff: limmaPval = 0.1; Fold-change cutoff: limmaFC = 1.3; Promoter analysis for DEGs: radio.promoter = 300 bp) were used to generate volcano plots and heatmaps. Volcano plots were generated with the web app, VolcaNoseR (<https://huygens.science.uva.nl/VolcaNoseR/>). Heatmaps were generated with a web server, Morpheus (<https://software.broadinstitute.org/morpheus/>). Pathway enrichment analysis was carried out through String API for Go Biological Process, Go Cellular Component, Go Molecular Function and KEGG at FDR cutoff = 0.01. GSEA was carried out with the following parameters: FDR cutoff: pathwayPvalCutoff = 0.2; Min size for gene set: minSetSize = 15; Max size for gene set: maxSetSize = 2000.

4.8. RNA seq

Total RNA was isolated using a Qiagen total RNA kit as per manufacturer protocol. After DNase treatment, RNA quality was assessed by bioanalyzer. RNA sequencing was performed with 40 M depth at the Columbia Genome Center using the Illumina HiSeq 2500 platform. GSEA was carried out with GSEA tool from Broad Institute (<http://www.gsea-msigdb.org/gsea/index.jsp>).

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.yjmcc.2022.02.003>.

Funding sources

This work was supported by the Schwartz Foundation [to AGF, BF and GVN], National Institutes of Health [R01 HL076485 to GVN, UH3 EB025765 to GVN, P41 EB027062 to GVN, K08HL140201 to BF]; National Science Foundation [NSF16478 to GVN]; European Molecular Biology Organization [EMBO ASTF 497-2012 to NbxB], the Dutch Heart Foundation [DHF-2014T013 to NbxB], and Natural Sciences and Engineering Research Council of Canada Postdoctoral fellowship [to

YZhao]; We thank the New York State Stem Cell Science Board (NYSTEM) for support under contract #C02361 (GVN and LMB) with matching funds from Columbia University for funding of the mass spectrometer.

Declaration of Competing Interest

The authors disclose no conflict of interest.

Acknowledgements

The authors would like to thank Dr. Mark C. van Turnhout for the in-house designed Matlab scripts. David Chen for initial processing of the mass spectrometry data and Davey Liu for uploading the raw mass spectrometry files to the data archive. We also thank Dr Paolo Colombo and Dr Veli Topkara for their help with the procurement of patients' samples and constructive discussions. This paper is dedicated to memory of Andrey Bondarenko (01/06/1968 - 5/27/2019), the developer and architect of the Rosetta Elucidator software who helped our team learn and perform proteomic data analysis.

References

- S.S. Virani, et al., Heart disease and stroke statistics-2020 update: a report from the American Heart Association, *Circulation* 141 (9) (2020) e139–e596.
- F. Follath, Ischemic versus non-ischemic heart failure: should the etiology be determined? *Heart Fail. Monit.* 1 (4) (2001) 122–125.
- Z.H. Zhang, et al., Clinical characteristics and long-term prognosis of ischemic and non-ischemic cardiomyopathy, *Indian Heart J.* 72 (2) (2020) 93–100.
- A.C. Ng, et al., Differences in management and outcome of ischemic and non-ischemic cardiomyopathy, *Int. J. Cardiol.* 129 (2) (2008) 198–204.
- S.F. Badylak, The extracellular matrix as a scaffold for tissue reconstruction, *Semin. Cell Dev. Biol.* 13 (5) (2002) 377–383.
- S.F. Badylak, Xenogeneic extracellular matrix as a scaffold for tissue reconstruction, *Transpl. Immunol.* 12 (3–4) (2004) 367–377.
- G.E. Davis, et al., Regulation of tissue injury responses by the exposure of matrix cryptic sites within extracellular matrix molecules, *AJPA* 156 (5) (2000) 1489–1498.
- T. Tønnessen, C.W. Knudsen, Surgical left ventricular remodeling in heart failure, *Eur. J. Heart Fail.* 7 (5) (2005) 704–709.
- H. Lodish, et al., *Molecular Cell Biology* 5th Edition, Modern Genetic Analysis 2nd Edition & Cd-rom, W H Freeman & Company, 2004.
- G.M. Fomovsky, S. Thomopoulos, J.W. Holmes, Contribution of extracellular matrix to the mechanical properties of the heart, *J. Mol. Cell. Cardiol.* (2009) 1–7.
- M. Rienks, et al., Myocardial extracellular matrix: an ever-changing and diverse entity, *Circ. Res.* 114 (5) (2014) 872–888.
- S. van Putten, Y. Shafieyan, B. Hinz, Mechanical control of cardiac myofibroblasts, *J. Mol. Cell. Cardiol.* 93 (2016) 133–142.
- E. Huang, et al., The roles of immune cells in the pathogenesis of fibrosis, *Int. J. Mol. Sci.* 21 (15) (2020) 5203.
- N.G. Frangogiannis, The extracellular matrix in ischemic and nonischemic heart failure, *Circ. Res.* 125 (1) (2019) 117–146.
- S.F. Badylak, et al., The use of extracellular matrix as an inductive scaffold for the partial replacement of functional myocardium, *Cell Transplant.* 15 (Suppl. 1) (2006) S29–S40.
- H.C. Ott, et al., Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart, *Nat. Med.* 14 (2) (2008) 213–221.
- Y. Chang, et al., Tissue regeneration observed in a basic fibroblast growth factor-loaded porous acellular bovine pericardium populated with mesenchymal stem cells, *J. Thorac. Cardiovasc. Surg.* 134 (1) (2007) (p. 65-73.e1-4).
- H.-J. Wei, et al., Porous acellular bovine pericardium seeded with mesenchymal stem cells as a patch to repair a myocardial defect in a syngeneic rat model, *Biomaterials* 27 (31) (2006) 5409–5419.
- S.F. Badylak, Regenerative medicine and developmental biology: the role of the extracellular matrix, *Anatom. Rec.* B 287 (1) (2005) 36–41.
- P.M. Crapo, Y. Wang, Small intestinal submucosa gel as a potential scaffolding material for cardiac tissue engineering, *Acta Biomater.* 6 (6) (2010) 2091–2096.
- S.B. Seif-Naraghi, et al., Patient-to-patient variability in autologous pericardial matrix scaffolds for cardiac repair, *J. Cardiovasc. Transl. Res.* 4 (5) (2011) 545–556.
- D.O. Freytes, et al., Preparation and rheological characterization of a gel form of the porcine urinary bladder matrix, *Biomaterials* 29 (11) (2008) 1630–1637.
- Y.D. Lin, et al., Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair, *Sci. Transl. Med.* 4 (146) (2012) (p. 146ra109-146ra109).
- Y. Duan, et al., Hybrid gel composed of native heart matrix and collagen induces cardiac differentiation of human embryonic stem cells without supplemental growth factors, *J. Cardiovasc. Transl. Res.* 4 (5) (2011) 605–615.
- D.O. Freytes, et al., Natural cardiac extracellular matrix hydrogels for cultivation of human stem cell-derived cardiomyocytes, *Methods Mol. Biol.* 1181 (2014) 69–81.
- A.F. Godier-Furnemont, et al., Composite scaffold provides a cell delivery platform for cardiovascular repair, *Proc. Natl. Acad. Sci. U. S. A.* 108 (19) (2011) 7974–7979.
- A. Critsinelis, et al., Left ventricular recovery with explantation of continuous-flow left ventricular assist device after 5 years of support, *Ann. Thorac. Cardiovasc. Surg.* 27 (3) (2021) 211–214.
- D.J. Goldstein, et al., Young patients with nonischemic cardiomyopathy have higher likelihood of left ventricular recovery during left ventricular assist device support, *J. Card. Fail.* 18 (5) (2012) 392–395.
- O. Wever-Pinzon, et al., Cardiac recovery during long-term left ventricular assist device support, *J. Am. Coll. Cardiol.* 68 (14) (2016) 1540–1553.
- E.J. Birks, et al., Prospective multicenter study of myocardial recovery using left ventricular assist devices (RESTAGE-HF [remission from stage D heart failure]): medium-term and primary end point results, *Circulation* 142 (21) (2020) 2016–2028.
- O.H. Frazier, et al., Ventricular reconditioning and pump explantation in patients supported by continuous-flow left ventricular assist devices, *J. Heart Lung Transplant.* 34 (6) (2015) 766–772.
- A.J. Engler, et al., Matrix elasticity directs stem cell lineage specification, *Cell* 126 (4) (2006) 677–689.
- W. Zhang, Y. Liu, H. Zhang, Extracellular matrix: an important regulator of cell functions and skeletal muscle development, *Cell Biosci.* 11 (1) (2021) 65.
- M. Kosuge, et al., Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes, *Circ. J.* 71 (2) (2007) 186–190.
- B.D. Johnson, et al., Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE), *Circulation* 109 (6) (2004) 726–732.
- P.M. Lepper, et al., Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease—results from the Ludwigshafen Risk and Cardiovascular Health Study (LURIC), *Atherosclerosis* 219 (1) (2011) 291–297.
- J. Murray, et al., The subunit composition of the human NADH dehydrogenase obtained by rapid one-step immunopurification, *J. Biol. Chem.* 278 (16) (2003) 13619–13622.
- J.L. Loeffen, et al., cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed, *Biochem. Biophys. Res. Commun.* 253 (2) (1998) 415–422.
- F. Bai, L. Wang, M. Kawai, A study of tropomyosin's role in cardiac function and disease using thin-filament reconstituted myocardium, *J. Muscle Res. Cell Motil.* 34 (3–4) (2013) 295–310.
- W. Yang, et al., Reynoutrin improves ischemic heart failure in rats via targeting S100A1, *Front. Pharmacol.* 12 (2021), 703962.
- J. Ritterhoff, P. Most, Targeting S100A1 in heart failure, *Gene Ther.* 19 (6) (2012) 613–621.
- B.V. Alvarez, et al., Quantification of carbonic anhydrase gene expression in ventricle of hypertrophic and failing human heart, *BMC Cardiovasc. Disord.* 13 (2013) 2.
- D. Torella, et al., Carbonic anhydrase activation is associated with worsened pathological remodeling in human ischemic diabetic cardiomyopathy, *J. Am. Heart Assoc.* 3 (2) (2014), e000434.
- S.A. Thompson, et al., Acute slowing of cardiac conduction in response to myofibroblast coupling to cardiomyocytes through N-cadherin, *J. Mol. Cell. Cardiol.* 68 (2014) 29–37.
- K. Zhang, et al., Asporin is a potential promising biomarker for common heart failure, *DNA Cell Biol.* 40 (2) (2021) 303–315.
- Y. Zhao, et al., A platform for generation of chamber-specific cardiac tissues and disease modeling, *Cell* 176 (4) (2019) 913–927 e18.
- K. Ronaldson-Bouchard, et al., Advanced maturation of human cardiac tissue grown from pluripotent stem cells, *Nature* 556 (7700) (2018) 239–243.
- D.J. Richards, et al., Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity, *Nat. Biomed. Eng.* 4 (4) (2020) 446–462.
- B.L. Bader, et al., Compound genetic ablation of nidogen 1 and 2 causes basement membrane defects and perinatal lethality in mice, *Mol. Cell. Biol.* 25 (15) (2005) 6846–6856.
- E.H. Kim, et al., Differential protein expression and basal lamina remodeling in human heart failure, *Proteom. Clin. Appl.* 10 (5) (2016) 585–596.
- M. Battle, et al., Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling, *Transplant. Proc.* 41 (6) (2009) 2231–2233.
- S. Takemoto, et al., Increased expression of dermatopontin mRNA in the infarct zone of experimentally induced myocardial infarction in rats: comparison with decorin and type I collagen mRNAs, *Basic Res. Cardiol.* 97 (6) (2002) 461–468.
- A. Ahmed, et al., Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics, *ESC Heart Fail.* 7 (1) (2020) 223–234.
- A. van Dijk, et al., Accumulation of fibronectin in the heart after myocardial infarction: a putative stimulator of adhesion and proliferation of adipose-derived stem cells, *Cell Tissue Res.* 332 (2) (2008) 289–298.
- I. Valiente-Alandi, et al., Inhibiting fibronectin attenuates fibrosis and improves cardiac function in a model of heart failure, *Circulation* 138 (12) (2018) 1236–1252.

- [56] A. Protti, et al., Assessment of myocardial remodeling using an elastin/tropoelastin specific agent with high field magnetic resonance imaging (MRI), *J. Am. Heart Assoc.* 4 (8) (2015), e001851.
- [57] S. Nehra, R.J. Gumina, S.S. Bansal, Immune cell dilemma in ischemic cardiomyopathy: to heal or not to heal, *Curr. Opin. Physiol.* 19 (2021) 39–46.
- [58] D.J. Tschumperlin, et al., Mechanosensing and fibrosis, *J. Clin. Invest.* 128 (1) (2018) 74–84.
- [59] A. Chopra, et al., Cardiac myocyte remodeling mediated by N-cadherin-dependent mechanosensing, *Am. J. Physiol. Heart Circ. Physiol.* 300 (4) (2011) H1252–H1266.
- [60] T.A. Quinn, P. Kohl, Cardiac mechano-electric coupling: acute effects of mechanical stimulation on heart rate and rhythm, *Physiol. Rev.* 101 (1) (2021) 37–92.
- [61] T.A. Quinn, Cardiac mechano-electric coupling: a role in regulating normal function of the heart? *Cardiovasc. Res.* 108 (1) (2015) 1–3.
- [62] R. Lock, et al., A framework for developing sex-specific engineered heart models, *Nat. Rev. Mater.* (2021) 1–19.
- [63] L.Q. Wan, et al., Micropatterned mammalian cells exhibit phenotype-specific left-right asymmetry, *Proc. Natl. Acad. Sci. U. S. A.* 108 (30) (2011) 12295–12300.
- [64] L. Yang, et al., Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population, *Nature* 453 (7194) (2008) 524–528.
- [66] M. Yazawa, et al., Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome, *Nature* 471 (7337) (2011) 230–234.
- [67] G. Eng, et al., Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes, *Nat. Commun.* 7 (2016) 10312.
- [68] A. Kamgoue, et al., Quantification of cardiomyocyte contraction based on image correlation analysis, *Cytometry A* 75 (4) (2009) 298–308.
- [69] D. Moran, et al., Data-independent acquisition (MSE) with ion mobility provides a systematic method for analysis of a bacteriophage structural proteome, *J. Virol. Methods* 195 (2014) 9–17.
- [70] M.K. Lin, et al., HTRA1, an age-related macular degeneration protease, processes extracellular matrix proteins EFEMP1 and TSP1, *Aging Cell* 17 (4) (2018), e12710.
- [71] E. Alegre-Aguaron, et al., Growth factor priming differentially modulates components of the extracellular matrix proteome in chondrocytes and synovium-derived stem cells, *PLoS One* 9 (2) (2014), e88053.
- [72] S.X. Ge, E.W. Son, R. Yao, iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data, *BMC Bioinformatics* 19 (1) (2018) 534.